Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -230187.80% is in line with its 5-year average of -215452.89%, near the high end of its 5-year range (-1237083.35%–20574.55%).
39.99% above its 12-month average of -383577.38%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2025 (2025-12-31): -111026.92%.
EBITDA MARGIN
-230187.80%
EBITDA MARGIN AVG TTM
-383577.38%
EBITDA MARGIN AVG 3Y
-304026.36%
EBITDA MARGIN AVG 5Y
-215452.89%
EBITDA MARGIN AVG 10Y
-34898.96%
EBITDA MARGIN AVG 15Y
-11783.46%
EBITDA MARGIN AVG 20Y
-257.22%
CURRENT VS TTM AVG
+39.99%
CURRENT VS 3Y AVG
+24.29%
CURRENT VS 5Y AVG
-6.84%
CURRENT VS 10Y AVG
-559.58%
CURRENT VS 15Y AVG
-1853.48%
CURRENT VS 20Y AVG
-89391.29%
Altimmune, Inc.
Market Cap
$519.25M
EBITDA Margin
-230187.80%
TTM Avg
-383577.38%
3Y Avg
-304026.36%
5Y Avg
-215452.89%
Market Cap
$517.79M
EBITDA Margin
-1406.75%
TTM Avg
-1406.75%
3Y Avg
-151851.64%
5Y Avg
-92301.39%
Market Cap
$517.73M
EBITDA Margin
-1179818.18%
TTM Avg
-754929.09%
3Y Avg
-428982.67%
5Y Avg
-428982.67%
Market Cap
$547.86M
EBITDA Margin
1.18%
TTM Avg
-15.78%
3Y Avg
-775.36%
5Y Avg
-845.24%
Market Cap
$487.30M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$481.33M
EBITDA Margin
-41.77%
TTM Avg
-67.13%
3Y Avg
-207.81%
5Y Avg
-270.93%
Market Cap
$478.54M
EBITDA Margin
-31.76%
TTM Avg
-31.76%
3Y Avg
-31.76%
5Y Avg
-31.76%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Altimmune, Inc. (ALT) | $519.25M | -230187.80% | -383577.38% | -304026.36% | -215452.89% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -1406.75% | -1406.75% | -151851.64% | -92301.39% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | -1179818.18% | -754929.09% | -428982.67% | -428982.67% |
| Evolus, Inc. (EOLS)vs › | $491.93M | -9.71% | -10.19% | -20.82% | -63.11% |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | 0.24% | -1.36% | -6.49% | -5.53% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 1.18% | -15.78% | -775.36% | -845.24% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $481.33M | -41.77% | -67.13% | -207.81% | -270.93% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -31.76% | -31.76% | -31.76% | -31.76% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | -27.54% | -4.08% | -49.61% | -102.69% |
Gross Margin
100.0%
EBITDA Margin
-230187.8%
Operating Margin
-230461.0%
Net Margin
-296000.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -111026.92% |
| 2025-09-30 | -416640.00% |
| 2025-06-30 | -457840.00% |
| 2025-03-31 | -435720.00% |
| 2024-12-31 | -496660.00% |
| 2024-09-30 | -494600.00% |
| 2024-06-30 | -533680.00% |
| 2024-03-31 | -533740.00% |
| 2023-12-31 | -85764.86% |
| 2023-09-30 | -6193.09% |
| 2023-06-30 | -298033.33% |
| 2023-03-31 | -103019.05% |
| 2022-12-31 | 20574.55% |
| 2022-09-30 | -1237083.35% |
| 2022-06-30 | -254275.00% |
| 2022-03-31 | -60562.50% |
| 2021-12-31 | -728.35% |
| 2021-09-30 | -20834.81% |
| 2021-06-30 | -18094.16% |
| 2021-03-31 | -1764.56% |
| 2020-12-31 | -455.74% |
| 2020-09-30 | -621.22% |
| 2020-06-30 | -2542.18% |
| 2020-03-31 | -326.90% |
| 2019-12-31 | -736.67% |
| 2019-09-30 | -1737.00% |
| 2019-06-30 | -213.74% |
| 2019-03-31 | -73.57% |
| 2018-12-31 | -1052.10% |
| 2018-09-30 | -150.82% |
| 2018-06-30 | -222.10% |
| 2018-03-31 | -120592.77% |
| 2017-12-31 | -445.99% |
| 2017-09-30 | -673.24% |
| 2017-06-30 | -80605.37% |
| 2017-03-31 | -391.80% |
| 2016-12-31 | -489.50% |
| 2016-09-30 | -398.19% |
| 2016-06-30 | -22.13% |
| 2016-03-31 | -120.98% |
| 2015-12-31 | -71.67% |
| 2015-09-30 | -140.46% |
| 2015-06-30 | -167.73% |
| 2015-03-31 | 16.95% |
| 2014-12-31 | -141.64% |
| 2014-09-30 | -411.34% |
| 2014-06-30 | -30.98% |
| 2014-03-31 | -63.11% |
| 2013-12-31 | -137.50% |
| 2013-09-30 | -90.44% |
| 2013-06-30 | -33.52% |
| 2013-03-31 | -16.03% |
| 2012-12-31 | -22.58% |
| 2012-09-30 | -25.66% |
| 2012-06-30 | -21.87% |
| 2012-03-31 | -24.47% |
| 2011-12-31 | -15.55% |
| 2011-09-30 | -55.27% |
| 2011-06-30 | -46.11% |
| 2011-03-31 | -69.78% |
| 2010-12-31 | -101.88% |
| 2010-09-30 | -49.75% |
| 2010-06-30 | -110.52% |
| 2010-03-31 | -229.78% |
| 2009-12-31 | -81.53% |
| 2009-09-30 | -106.56% |
| 2009-06-30 | -82.79% |
| 2009-03-31 | -94.30% |
| 2008-12-31 | -83.90% |
| 2008-09-30 | -35.28% |
| 2008-06-30 | -195.68% |
| 2008-03-31 | -80.61% |
| 2007-12-31 | -87.07% |
| 2007-09-30 | -101.60% |
| 2007-06-30 | 107.12% |
| 2007-03-31 | 74.43% |
| 2006-12-31 | 54.63% |
| 2006-09-30 | 74.13% |
| 2006-06-30 | 72.50% |
| 2006-03-31 | 58.63% |
| 2005-12-31 | 45.11% |
| 2005-09-30 | 75.86% |
